Puma Biotechnology Gets Orphan Designation for Small Cell Lung Cancer Drug
2023年9月22日 - 5:55AM
Dow Jones News
By Sabela Ojea
Puma Biotechnology said the Food and Drug Administration granted
orphan drug designation to its alisertib drug, aimed at treating
small cell lung cancer, an aggressive of the disease.
The biopharmaceutical company said it is now working to begin
the Phase II trial of alisertib.
Orphan drug designations are granted to drugs or biologics used
for the treatment, prevention or diagnosis of a rare disease that
affects less than 200,000 people in the U.S.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 21, 2023 16:40 ET (20:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Puma Biotechnology (NASDAQ:PBYI)
過去 株価チャート
から 4 2024 まで 5 2024
Puma Biotechnology (NASDAQ:PBYI)
過去 株価チャート
から 5 2023 まで 5 2024